BioSpace News Archive

Orion’s collaboration partner Bayer announced the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral androgen receptor inhibitor darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced it has appointed Douglas Warner, M.D., as chief medical officer.

Harbour BioMed announced that the preclinical results of porustobart, a next-generation fully human heavy-chain antibody with a Treg depletion mechanism, were published in the Proceedings of the National Academy of Sciences.

HUTCHMED and AstraZeneca announce that preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO® plus savolitinib demonstrated an objective response rate of 49% in patients with epidermal growth factor receptor-mutated non-small cell lung cancer with high levels of mesenchymal epithelial transition overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with TAGRISSO®.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Protalix BioTherapeutics, Inc. today announced that it will release its financial results for the second quarter 2022 and provide a business update on Monday, August 15, 2022.

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for 124 I-AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of transthyretin amyloidosis (ATTR).

LENSAR, Inc. today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives.

Foundation Medicine, Inc., Flatiron Health, and Genentech, members of the Roche Group, in partnership with a network of community oncology practices, today announced new research in the Journal of Thoracic Oncology Clinical and Research Reports.

NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of new members of its Scientific Advisory Board.